Gender (male), n (%)
|
53 (88.3)
|
49 (81.7)
|
102 (85.0)
|
48 (87.3)
|
47 (81.0)
|
95 (84.1)
|
Age (years), mean (SD)
|
46.2 (13.7)
|
43.7 (12.4)
|
44.9 (13.1)
|
47.2 (13.6)
|
43.6 (12.4)
|
45.6 (13.0)
|
BMI, mean (SD)
|
25.9 (3.4)
|
25.8 (3.8)
|
25.9 (3.6)
|
25.8 (3.4)
|
25.9 (3.8)
|
25.9 (3.6)
|
Years from diagnosis, median (P25, P75)
|
10.4 (7.1, 20.8)
|
9.3 (5.2, 17.6)
|
10.0 (5.9, 19.8)
|
10.4 (7.1, 22.6)
|
9.3 (5.0, 19.0)
|
10.0 (5.9, 20.3)
|
ASAS criteria for sacroilitis, n (%)
|
58 (96.7)
|
59 (98.3)
|
117 (97.5)
|
53 (96.4)
|
57 (98.3)
|
110 (97.3)
|
ASDAS-CRP, median (P25, P75)
|
0.7 (0.5, 1.1)
|
0.7 (0.5, 1.1)
|
0.7 (0.5, 1.1)
|
1.1 (0.8, 3.5)
|
1.0 (0.7, 1.9)
|
1.1 (0.7, 2.0)
|
BASDAI, median (P25, P75)
|
1.0 (0.6, 1.7)
|
1.0 (0.2, 1.4)
|
1.0 (0.4, 1.6)
|
1.0 (0.6, 1.7)
|
1.0 (0.2, 1.4)
|
1.0 (0.4, 1.6)
|
VAS nocturnal axial pain, mean (SD)
|
0.85 (1.0)
|
1.03 (1.16)
|
0.94 (1.09)
|
0.84 (1.01)
|
1.02 (1.15)
|
0.93 (1.08)
|
IGA, median (P25, P75)
|
1.0 (0.0, 2.0)
|
1.0 (0.0, 1.0)
|
1.0 (0.0, 1.0)
|
1.0 (0.0, 2.0)
|
1.0 (0.0, 1.0)
|
1.0 (0.0, 1.0)
|
PGA, median (P25, P75)
|
1.0 (0.0, 2.0)
|
1.0 (0.0, 2.0)
|
1.0 (0.0, 2.0)
|
1.0 (0.0, 2.0)
|
1.0 (0.0, 1.0)
|
1.0 (0.0, 1.0)
|
Current TNFi, n (%)
|
Adalimumab
|
24 (40.0)
|
23 (38.3)
|
47 (39.2)
|
22 (40.0)
|
22 (37.9)
|
44 (38.9)
|
Etanercept
|
21 (35.0)
|
20 (33.3)
|
41 (34.2)
|
19 (34.5)
|
19 (32.8)
|
38 (33.6)
|
Golimumab
|
4 (6.7)
|
5 (8.3)
|
9 (7.5)
|
4 (7.3)
|
5 (8.6)
|
9 (8.0)
|
Infliximab
|
11 (18.3)
|
12 (20.0)
|
23 (19.2)
|
10 (18.2)
|
12 (20.7)
|
22 (19.5)
|
N of previous TNFi, n (%)
|
None
|
50 (83.3)
|
44 (73.3)
|
94 (78.3)
|
46 (83.6)
|
42 (72.41)
|
88 (77.9)
|
One
|
10 (16.7)
|
11 (18.3)
|
21 (17.5)
|
9 (16.4)
|
11 (19.0)
|
20 (17.7)
|
Two
|
0 (0.0)
|
5 (8.3)
|
5 (4.2)
|
0 (0.0)
|
5 (8.6)
|
5 (4.4)
|
NSAID use, n (%)
|
16 (26.7)
|
14 (23.3)
|
28 (24.8)
|
15 (27.3)
|
13 (22.4)
|
28 (24.8)
|